MediciNova (MNOV) has received a Notice of Allowance from the USPTO for a pending patent application for MN-001 – Tipelukast – to ...

HealthTab™ has proven that it can rapidly scale nationally and elevate patient and practitioner experience with point-of-care ...

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange ...

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug ...

As the U.S. stock market takes a breather following a post-election rally, investors are keenly observing opportunities that might arise in different sectors. Penny stocks, despite their somewhat ...

MediciNova Inc. (MNOV) on Wednesday reported a loss of $2.9 million in its third quarter. On a per-share basis, the La ...

MediciNova (MNOV) was notified by Sanofi (SNY) that the Sanofi/Novartis (NVS) litigation was settled. Accordingly, MediciNova is entitled to ...

Logistics segment delivered volume growth of 24%, resulting in 18% growth in revenue year-over-year. US revenue increased 19% ...

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of ...

The severe asthma market is fueled by the rising prevalence of the condition, particularly in urban areas, alongside the emergence of innovative therapies ...

StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Free Report) in a report released on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. MediciNova ...